NCT01804244View on ClinicalTrials.gov

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

TMC278

1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.

Trial Locations (1)

Unknown

Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY